| Host |
Monospecific Mouse |
| Klon |
ZM11 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Lung adenocarcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant fragment of human napsin protein |
| Lokalisation |
Cytoplasm |
Napsin A
|
Zeta Corporation |
ZM11 |
1 ml |
Concentrate |
CE/IVD |
Z2294ML |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM11 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Lung adenocarcinoma. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant fragment of human napsin protein |
| Lokalisation |
Cytoplasm |
Napsin A
|
Zeta Corporation |
ZM11 |
7 ml |
Ready-to-use |
CE/IVD |
Z2294MP |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM11 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Lung adenocarcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant fragment of human napsin protein |
| Lokalisation |
Cytoplasm |
Napsin A
|
Zeta Corporation |
ZM11 |
0.5 ml |
Concentrate |
CE/IVD |
Z2294MS |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM11 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Lung adenocarcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant fragment of human napsin protein |
| Lokalisation |
Cytoplasm |
Napsin A
|
Zeta Corporation |
ZM11 |
0.1 ml |
Concentrate |
CE/IVD |
Z2294MT |
-
|
| Host |
Goat |
| Klon |
polyclonal |
| Format |
Purified |
| Methode |
WB |
| Verdünnung |
0,2 - 2 µg/mL |
| Isotyp |
Goat IgG |
| Verdünnung |
Peptide sequence CSESTKRKLASAV corresponding to the C-terminus of NCF1 (NP_000256) |
NCF1 (Neutrophil Cytosolic Factor 1, p47 phox)
|
Zytomed Systems GmbH |
polyclonal |
100 µg |
Purified |
RUO |
614-0007 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Purified |
| Methode |
F, IF, EL, WB |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Whole cell preparation of N.meningitidis types A, B and C |
Neisseria meningitidis
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Purified |
RUO |
614-0015 |
-
|
| Host |
Rabbit |
| Klon |
EP31 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Neuronal tissues, pancreas |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasmic |
Nerve Growth Factor Receptor
|
Biocare Medical |
EP31 |
0.1 ml |
Concentrate |
CE/IVD |
ACI369A |
-
|
| Host |
Rabbit |
| Klon |
SP103 |
| Format |
Concentrate |
| Methode |
P, WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Kidney |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to C-terminus of human nestin |
| Lokalisation |
Cytoplasm |
Nestin
|
Zytomed Systems GmbH |
SP103 |
0.1 ml |
Concentrate |
RUO |
514-4030 |
-
|
| Host |
Rabbit |
| Klon |
SP103 |
| Format |
Concentrate |
| Methode |
P, WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Kidney |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to C-terminus of human nestin |
| Lokalisation |
Cytoplasm |
Nestin
|
Zytomed Systems GmbH |
SP103 |
0.5 ml |
Concentrate |
RUO |
514-4032 |
-
|
| Host |
Rabbit |
| Klon |
SP103 |
| Format |
Concentrate |
| Methode |
P, WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Kidney |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to C-terminus of human nestin |
| Lokalisation |
Cytoplasm |
Nestin
|
Zytomed Systems GmbH |
SP103 |
1 ml |
Concentrate |
RUO |
514-4034 |
-
|
| Host |
Mouse |
| Klon |
10C2 |
| Format |
Purified |
| Methode |
F, P |
| Verdünnung |
1:50 - 1:200 |
| Isotyp |
Mouse IgG1 |
Nestin
|
Zytomed Systems GmbH |
10C2 |
100 µg |
Purified |
RUO |
614-0021 |
-
|
| Host |
Mouse |
| Klon |
A60 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Brain tissue. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 |
| Verdünnung |
Purified cell nuclei from mouse brain |
| Lokalisation |
Nucleus |
NeuN
|
Zeta Corporation |
A60 |
1 ml |
Concentrate |
CE/IVD |
Z2178ML |
-
|
| Host |
Mouse |
| Klon |
A60 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Brain tissue. |
| Verdünnung |
- |
| Isotyp |
IgG1 |
| Verdünnung |
Purified cell nuclei from mouse brain |
| Lokalisation |
Nucleus |
NeuN
|
Zeta Corporation |
A60 |
7 ml |
Ready-to-use |
CE/IVD |
Z2178MP |
-
|
| Host |
Mouse |
| Klon |
A60 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Brain tissue. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 |
| Verdünnung |
Purified cell nuclei from mouse brain |
| Lokalisation |
Nucleus |
NeuN
|
Zeta Corporation |
A60 |
0.5 ml |
Concentrate |
CE/IVD |
Z2178MS |
-
|
| Host |
Mouse |
| Klon |
A60 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Brain tissue. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 |
| Verdünnung |
Purified cell nuclei from mouse brain |
| Lokalisation |
Nucleus |
NeuN
|
Zeta Corporation |
A60 |
0.1 ml |
Concentrate |
CE/IVD |
Z2178MT |
-
|
| Host |
Rabbit |
| Klon |
ZR386 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Brain tissue |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa1-200) of human RBFOX3 (NeuN) protein (exact sequence is proprietary) |
| Lokalisation |
Cytoplasm |
NeuN
|
Zeta Corporation |
ZR386 |
1 ml |
Concentrate |
CE/IVD |
Z2677RL |
-
|
| Host |
Rabbit |
| Klon |
ZR386 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Brain tissue |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa1-200) of human RBFOX3 (NeuN) protein (exact sequence is proprietary) |
| Lokalisation |
Cytoplasm |
NeuN
|
Zeta Corporation |
ZR386 |
7 ml |
Concentrate |
CE/IVD |
Z2677RP |
-
|
| Host |
Rabbit |
| Klon |
ZR386 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Brain tissue |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa1-200) of human RBFOX3 (NeuN) protein (exact sequence is proprietary) |
| Lokalisation |
Cytoplasm |
NeuN
|
Zeta Corporation |
ZR386 |
0.5 ml |
Concentrate |
CE/IVD |
Z2677RS |
-
|
| Host |
Rabbit |
| Klon |
ZR386 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Brain tissue |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa1-200) of human RBFOX3 (NeuN) protein (exact sequence is proprietary) |
| Lokalisation |
Cytoplasm |
NeuN
|
Zeta Corporation |
ZR386 |
0.1 ml |
Concentrate |
CE/IVD |
Z2677RT |
-
|
| Host |
Mouse |
| Klon |
2F11 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Brain. |
| Verdünnung |
1:50 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Human NF-H isolated brain cells |
| Lokalisation |
Cytoplasm |
Neurofilament
|
Zeta Corporation |
2F11 |
1ml |
Concentrate |
CE/IVD |
Z2091ML |
-
|
| Host |
Mouse |
| Klon |
2F11 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Brain. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Human NF-H isolated brain cells |
| Lokalisation |
Cytoplasm |
Neurofilament
|
Zeta Corporation |
2F11 |
7 ml |
Ready-to-use |
CE/IVD |
Z2091MP |
-
|
| Host |
Mouse |
| Klon |
2F11 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Brain. |
| Verdünnung |
1:50 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Human NF-H isolated brain cells |
| Lokalisation |
Cytoplasm |
Neurofilament
|
Zeta Corporation |
2F11 |
0.5 ml |
Concentrate |
CE/IVD |
Z2091MS |
-
|
| Host |
Mouse |
| Klon |
2F11 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Brain. |
| Verdünnung |
1:50 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Human NF-H isolated brain cells |
| Lokalisation |
Cytoplasm |
Neurofilament
|
Zeta Corporation |
2F11 |
0.1 ml |
Concentrate |
CE/IVD |
Z2091MT |
-
|
| Host |
Rabbit |
| Klon |
ZR216 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Brain |
| Verdünnung |
1:100-200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human NEFL protein |
| Lokalisation |
Cytoplasmic |
Neurofilament
|
Zeta Corporation |
ZR216 |
1 ml |
Concentrate |
CE/IVD |
Z2706RL |
-
|
| Host |
Rabbit |
| Klon |
ZR216 |
| Format |
ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Brain |
| Verdünnung |
--- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human NEFL protein |
| Lokalisation |
Cytoplasmic |
Neurofilament
|
Zeta Corporation |
ZR216 |
7 ml |
ready-to-use |
CE/IVD |
Z2706RP |
-
|
| Host |
Rabbit |
| Klon |
ZR216 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Brain |
| Verdünnung |
1:100-200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human NEFL protein |
| Lokalisation |
Cytoplasmic |
Neurofilament
|
Zeta Corporation |
ZR216 |
0.5 ml |
Concentrate |
CE/IVD |
Z2706RS |
-
|
| Host |
Rabbit |
| Klon |
ZR216 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Brain |
| Verdünnung |
1:100-200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human NEFL protein |
| Lokalisation |
Cytoplasmic |
Neurofilament
|
Zeta Corporation |
ZR216 |
0.1 ml |
Concentrate |
CE/IVD |
Z2706RT |
-
|
| Host |
Mouse |
| Klon |
RT97 |
| Format |
Purified |
| Methode |
F, P |
| Vorbehandlung |
- |
| Positivkontrolle |
Brain, Spinal Cord |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Triton X-100-insoluble rat brain protein |
Neurofilament H (200 kDa)
|
Zytomed Systems GmbH |
RT97 |
100 µg |
Purified |
RUO |
614-0177 |
-
|
| Host |
Sheep |
| Klon |
polyclonal |
| Format |
Lyophilised |
| Methode |
WB, EL |
| Isotyp |
Sheep IgG |
| Verdünnung |
Affinity purified mouse 2.5S NGF |
NGF-beta (Nerve Growth Factor beta)
|
Zytomed Systems GmbH |
polyclonal |
1 mg |
Lyophilised |
RUO |
614-0070 |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM55 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Breast tissue. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human p75 NGFR protein fragment (around aa 281-421) |
| Lokalisation |
Cytoplasm |
NGFR
|
Zeta Corporation |
ZM55 |
1 ml |
Concentrate |
CE/IVD |
Z2365ML |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM55 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Breast tissue. |
| Verdünnung |
- |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human p75 NGFR protein fragment (around aa 281-421) |
| Lokalisation |
Cytoplasm |
NGFR
|
Zeta Corporation |
ZM55 |
7 ml |
Ready-to-use |
CE/IVD |
Z2365MP |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM55 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Breast tissue. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human p75 NGFR protein fragment (around aa 281-421) |
| Lokalisation |
Cytoplasm |
NGFR
|
Zeta Corporation |
ZM55 |
0.5 ml |
Concentrate |
CE/IVD |
Z2365MS |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM55 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Breast tissue. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human p75 NGFR protein fragment (around aa 281-421) |
| Lokalisation |
Cytoplasm |
NGFR
|
Zeta Corporation |
ZM55 |
0.1 ml |
Concentrate |
CE/IVD |
Z2365MT |
-
|
| Host |
Mouse |
| Klon |
DBM15.15 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Ewing's Sarcoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG2b k |
| Verdünnung |
Human full-length recombinant NKX2.2 protein |
| Lokalisation |
Nucleus |
NKX2.2
|
Diagnostic Biosystems |
DBM15.15 |
1 ml |
Concentrate |
CE/IVD |
MOB486 |
-
|
| Host |
Mouse |
| Klon |
DBM15.15 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Ewing's Sarcoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG2b k |
| Verdünnung |
Human full-length recombinant NKX2.2 protein |
| Lokalisation |
Nucleus |
NKX2.2
|
Diagnostic Biosystems |
DBM15.15 |
0.1 ml |
Concentrate |
CE/IVD |
MOB486-01 |
-
|
| Host |
Mouse |
| Klon |
DBM15.15 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Ewing's Sarcoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG2b k |
| Verdünnung |
Human full-length recombinant NKX2.2 protein |
| Lokalisation |
Nucleus |
NKX2.2
|
Diagnostic Biosystems |
DBM15.15 |
0.5 ml |
Concentrate |
CE/IVD |
MOB486-05 |
-
|
| Host |
Mouse |
| Klon |
DBM15.15 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Ewing's Sarcoma |
| Verdünnung |
- |
| Isotyp |
Mouse IgG2b k |
| Verdünnung |
Human full-length recombinant NKX2.2 protein |
| Lokalisation |
Nucleus |
NKX2.2
|
Diagnostic Biosystems |
DBM15.15 |
6 ml |
Ready-to-use |
CE/IVD |
PDM199 |
-
|
| Host |
Mouse |
| Klon |
DBM15.15 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Ewing's Sarcoma |
| Verdünnung |
- |
| Isotyp |
Mouse IgG2b k |
| Verdünnung |
Human full-length recombinant NKX2.2 protein |
| Lokalisation |
Nucleus |
NKX2.2
|
Diagnostic Biosystems |
DBM15.15 |
25 ml |
Ready-to-use |
CE/IVD |
PDM199-25 |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM14 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Ewing's sarcoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Human recombinant NKX2.2 protein fragment (aa1-119) |
| Lokalisation |
Nucleus |
NKX2.2
|
Zeta Corporation |
ZM14 |
1 ml |
Concentrate |
CE/IVD |
Z2348ML |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM14 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Ewing's sarcoma. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Human recombinant NKX2.2 protein fragment (aa1-119) |
| Lokalisation |
Nucleus |
NKX2.2
|
Zeta Corporation |
ZM14 |
7 ml |
Ready-to-use |
CE/IVD |
Z2348MP |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM14 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Ewing's sarcoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Human recombinant NKX2.2 protein fragment (aa1-119) |
| Lokalisation |
Nucleus |
NKX2.2
|
Zeta Corporation |
ZM14 |
0.5 ml |
Concentrate |
CE/IVD |
Z2348MS |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM14 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Ewing's sarcoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Human recombinant NKX2.2 protein fragment (aa1-119) |
| Lokalisation |
Nucleus |
NKX2.2
|
Zeta Corporation |
ZM14 |
0.1 ml |
Concentrate |
CE/IVD |
Z2348MT |
-
|
| Host |
Rabbit |
| Klon |
D2Y1A |
| Format |
concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Prostate cancer |
| Verdünnung |
1:100 |
| Isotyp |
IgG |
| Lokalisation |
Nucleus |
NKX3.1
|
Biocare Medical |
D2Y1A |
0.1 ml |
concentrate |
CE/IVD |
ACI3260A |
-
|
| Host |
Rabbit |
| Klon |
D2Y1A |
| Format |
concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Prostate cancer |
| Verdünnung |
1:100 |
| Isotyp |
IgG |
| Lokalisation |
Nucleus |
NKX3.1
|
Biocare Medical |
D2Y1A |
0.5 ml |
concentrate |
CE/IVD |
ACI3260B |
-
|
| Host |
Rabbit |
| Klon |
D2Y1A |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
CC1 |
| Positivkontrolle |
Prostate cancer |
| Verdünnung |
- |
| Isotyp |
IgG |
| Lokalisation |
Nucleus |
NKX3.1
|
Biocare Medical |
D2Y1A |
7 ml |
Ready-to-use |
CE/IVD |
ALI3260G7 |
-
|
| Host |
Rabbit |
| Klon |
D2Y1A |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Prostate cancer |
| Verdünnung |
- |
| Isotyp |
IgG |
| Lokalisation |
Nucleus |
NKX3.1
|
Biocare Medical |
D2Y1A |
6 ml |
Ready-to-use |
CE/IVD |
API3260AA |
-
|
| Host |
Rabbit |
| Klon |
D2Y1A |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
CC1 |
| Positivkontrolle |
Prostate cancer |
| Verdünnung |
- |
| Isotyp |
IgG |
| Lokalisation |
Nucleus |
NKX3.1
|
Biocare Medical |
D2Y1A |
6 ml |
Ready-to-use |
CE/IVD |
AVI3260G |
-
|
| Host |
Mouse |
| Klon |
361 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Prostate carcinoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1 kappa |
| Verdünnung |
Recombinant His fusion protein corresponding to full length human NKX3.1 |
| Lokalisation |
Nuclear |
NKX3.1
|
Diagnostic Biosystems |
361 |
1 ml |
Concentrate |
CE/IVD |
MOB569 |
-
|
| Host |
Mouse |
| Klon |
361 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Prostate carcinoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1 kappa |
| Verdünnung |
Recombinant His fusion protein corresponding to full length human NKX3.1 |
| Lokalisation |
Nuclear |
NKX3.1
|
Diagnostic Biosystems |
361 |
0.1 ml |
Concentrate |
CE/IVD |
MOB569-01 |
-
|
| Host |
Mouse |
| Klon |
361 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Prostate carcinoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1 kappa |
| Verdünnung |
Recombinant His fusion protein corresponding to full length human NKX3.1 |
| Lokalisation |
Nuclear |
NKX3.1
|
Diagnostic Biosystems |
361 |
0.5 ml |
Concentrate |
CE/IVD |
MOB569-05 |
-
|